Impact of genetic polymorphism of SDF1 3A on efficacy of captopril in Chinese patients with essential hypertension
10.3969/j.issn.1672-7347.2010.06.003
- VernacularTitle:SDF1 3A遗传多态性对高血压患者应用卡托普利疗效的影响
- Author:
Yan YAN
;
Chen NING
;
Huan ZHOU
;
Tianlun YANG
;
- Publication Type:Journal Article
- Keywords:
essential hypertension;
SDF-1;
SDF1 3A genetic polymorphism;
captopril;
nitrendipine
- From:
Journal of Central South University(Medical Sciences)
2010;35(6):549-556
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the association of SDF1 3A genetic polymorphism with susceptibility of essential hypertension and captopril efficacy in patients with essential hypertension.Methods A total of 214 patients with essential hypertension and 228 healthy controls were genotyped for SDF1 3A polymorphism by polymerase chain reaction-restriction fragment length polymorphism assay. Among 39 subjects with different SDF1 3A of genotypes, 13 hypertensive patients simultaneously took oral captopril (25 mg/d) and nitrendipine (30 mg/d), and 12 patients orally received nitrendipine alone for 8 consecutive weeks, and 14 healthy controls did not take any agents. The blood pressure of all subjects was measured to evaluate the therapeutic efficacy. Results There was a significant difference in the plasma SDF-1 level in individuals with AA+AG genotypes or GG genotypes of SDF1 3A treated with nitrendipine plus captopril compared with healthy control (P<0.05). Carriers with AA genotypes of SDF1 3A had lower total protein and globulin than those with GG genotypes (P<0.05). After captopril treatment, hypertensive patients with AA+AG genotypes had bigger attenuated systolic blood pressure compared with those with GG genotypes (P<0.05). Conclusion Genetic polymorphism of SDF1 3A could influence the therapeutic efficacy of captopril in Chinese hypertensive patients.
